Unum Therapeutics Receives $65,000,000 Series B Financing

  • Feed Type
  • Date
    6/11/2015
  • Company Name
    Unum Therapeutics
  • Mailing Address
    One Broadway 4th Floor Cambridge, MA 02142 USA
  • Company Description
    Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer.
  • Website
    http://www.unumrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $65,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds from the financing will be used to advance the Unum’s novel Antibody-Coupled T-cell Receptor (ACTR) technology platform and support the expansion of the company’s proprietary pipeline of ACTR therapies targeting a broad range of hematological and solid tumor targets.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy